Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Aclaris TherapeuticsLexicon PharmaceuticalsSyndax PharmaceuticalsFive Prime TherapeuticsPhibro Animal Health
SymbolNASDAQ:ACRSNASDAQ:LXRXNASDAQ:SNDXNASDAQ:FPRXNASDAQ:PAHC
Price Information
Current Price$27.75$5.12$21.03$37.95$23.96
52 Week RangeN/AHoldBuyHoldHold
MarketRank™
Overall Score0.81.61.61.41.8
Analysis Score0.03.13.42.10.8
Community Score2.62.52.52.72.2
Dividend Score0.00.00.00.02.5
Ownership Score0.81.71.71.71.7
Earnings & Valuation Score0.60.60.60.61.9
Analyst Ratings
Consensus RecommendationN/AHoldBuyHoldHold
Consensus Price TargetN/A$9.40$28.55$30.71$21.50
% Upside from Price TargetN/A83.59% upside35.74% upside-19.07% downside-10.27% downside
Trade Information
Market Cap$1.50 billion$775.18 million$1.07 billion$1.77 billion$992.72 million
Beta1.22.091.84.40.46
Average Volume2,806,4374,668,547672,2932,047,596144,758
Sales & Book Value
Annual Revenue$4.23 million$322.07 million$1.52 million$14.87 million$800.40 million
Price / Sales339.852.29667.37118.861.21
CashflowN/A$2.30 per shareN/AN/A$2.16 per share
Price / CashN/A2.23N/AN/A11.10
Book Value$1.69 per share$1.10 per share$1.16 per share$4.13 per share$4.65 per share
Price / Book16.424.6518.139.195.15
Profitability
Net Income$-161,350,000.00$130.13 million$-56,050,000.00$-137,200,000.00$33.55 million
EPS($2.25)$1.35($1.84)($3.92)$1.08
Trailing P/E RatioN/AN/AN/AN/A22.60
Forward P/E RatioN/AN/AN/AN/A21.20
P/E GrowthN/AN/AN/AN/A2.00
Net Margins-941.07%-320.44%-4,656.63%-554.71%5.37%
Return on Equity (ROE)-104.00%-164.96%-77.47%-75.84%23.70%
Return on Assets (ROA)-64.47%-31.83%-52.27%-49.08%5.99%
Dividend
Annual PayoutN/AN/AN/AN/A$0.48
Dividend YieldN/AN/AN/AN/A2.00%
Three-Year Dividend GrowthN/AN/AN/AN/A20.00%
Payout RatioN/AN/AN/AN/A44.44%
Years of Consecutive Dividend GrowthN/AN/AN/AN/A1 Years
Debt
Debt-to-Equity Ratio0.26%0.13%0.15%N/A1.97%
Current Ratio4.54%1.54%11.71%5.35%2.88%
Quick Ratio4.54%1.55%11.71%5.35%1.61%
Ownership Information
Institutional Ownership Percentage59.10%84.62%83.78%67.28%50.32%
Insider Ownership Percentage8.20%6.40%9.50%6.40%50.05%
Miscellaneous
Employees577843871,700
Shares Outstanding51.80 million144.35 million48.24 million46.57 million40.45 million
Next Earnings Date5/6/2021 (Estimated)4/26/2021 (Estimated)5/6/2021 (Estimated)5/6/2021 (Estimated)5/6/2021 (Confirmed)
OptionableOptionableOptionableOptionableOptionableOptionable
SourceHeadline
Phibro Animal Health Corporation to Host Webcast and Conference Call on March 2021 Quarterly Financial ResultsPhibro Animal Health Corporation to Host Webcast and Conference Call on March 2021 Quarterly Financial Results
finance.yahoo.com - April 8 at 6:32 PM
Phibro Animal Health Corporation to Participate in Bank of America Securities 2021 Virtual Healthcare ConferencePhibro Animal Health Corporation to Participate in Bank of America Securities 2021 Virtual Healthcare Conference
finance.yahoo.com - April 7 at 7:34 PM
PAHC or SRDX: Which Is the Better Value Stock Right Now?PAHC or SRDX: Which Is the Better Value Stock Right Now?
finance.yahoo.com - April 7 at 2:14 PM
Phibro Animal Health (PAHC)Phibro Animal Health (PAHC)
forbes.com - March 19 at 10:54 AM
Head-To-Head Review: Phibro Animal Health (NASDAQ:PAHC) vs. MorphoSys (NASDAQ:MOR)Head-To-Head Review: Phibro Animal Health (NASDAQ:PAHC) vs. MorphoSys (NASDAQ:MOR)
americanbankingnews.com - March 18 at 8:18 AM
Why Is Phibro (PAHC) Up 1.1% Since Last Earnings Report?Why Is Phibro (PAHC) Up 1.1% Since Last Earnings Report?
finance.yahoo.com - March 5 at 2:29 PM
Phibro Animal Health Corporation to Participate in the Barclays Virtual Global Healthcare ConferencePhibro Animal Health Corporation to Participate in the Barclays Virtual Global Healthcare Conference
finance.yahoo.com - February 8 at 5:48 PM
Phibro Animal Health Corporation to Participate in Bank of America Merrill Lynch 2021 Virtual Animal Health SummitPhibro Animal Health Corporation to Participate in Bank of America Merrill Lynch 2021 Virtual Animal Health Summit
finance.yahoo.com - February 8 at 12:47 PM
Phibro Animal Health Corporation Just Beat EPS By 28%: Heres What Analysts Think Will Happen NextPhibro Animal Health Corporation Just Beat EPS By 28%: Here's What Analysts Think Will Happen Next
nasdaq.com - February 5 at 9:43 AM
Phibro Animal Health Corp (PAHC) Q2 2021 Earnings Call TranscriptPhibro Animal Health Corp (PAHC) Q2 2021 Earnings Call Transcript
finance.yahoo.com - February 4 at 11:43 PM
Phibro Animal Health A is about to announce earnings — heres what Wall Street expectsPhibro Animal Health A is about to announce earnings — here's what Wall Street expects
markets.businessinsider.com - February 2 at 7:45 PM
PAHC vs. SRDX: Which Stock Should Value Investors Buy Now?PAHC vs. SRDX: Which Stock Should Value Investors Buy Now?
finance.yahoo.com - January 20 at 4:26 PM
Phirbo (PAHC) Nutritional Specialty Aids Growth, Low ASP AilsPhirbo (PAHC) Nutritional Specialty Aids Growth, Low ASP Ails
finance.yahoo.com - January 12 at 11:09 AM
Phibro Animal Health Corporation to Host Webcast and Conference Call on December 2020 Quarterly Financial ResultsPhibro Animal Health Corporation to Host Webcast and Conference Call on December 2020 Quarterly Financial Results
finance.yahoo.com - January 5 at 7:46 PM
Why Phibro Animal Health Corporation (NASDAQ:PAHC) Looks Like A Quality CompanyWhy Phibro Animal Health Corporation (NASDAQ:PAHC) Looks Like A Quality Company
finance.yahoo.com - December 25 at 3:00 PM
Phibro Animal Health: Not Overly Expensive At 10X Its EBITDAPhibro Animal Health: Not Overly Expensive At 10X Its EBITDA
seekingalpha.com - December 16 at 12:45 PM
Is PAHC A Good Stock To Buy Now?Is PAHC A Good Stock To Buy Now?
finance.yahoo.com - December 16 at 1:18 AM
Why Is Phibro (PAHC) Up 1.4% Since Last Earnings Report?Why Is Phibro (PAHC) Up 1.4% Since Last Earnings Report?
finance.yahoo.com - December 4 at 5:55 PM
Phibro (PAHC) Hurt by Adverse Pricing in Mineral Nutrition ArmPhibro (PAHC) Hurt by Adverse Pricing in Mineral Nutrition Arm
finance.yahoo.com - November 24 at 12:32 PM
An Intrinsic Calculation For Phibro Animal Health Corporation (NASDAQ:PAHC) Suggests Its 49% UndervaluedAn Intrinsic Calculation For Phibro Animal Health Corporation (NASDAQ:PAHC) Suggests It's 49% Undervalued
finance.yahoo.com - November 9 at 5:31 PM
Phibro Animal Health Corporation (PAHC) CEO Jack Bendheim on Q1 2021 Results - Earnings Call TranscriptPhibro Animal Health Corporation (PAHC) CEO Jack Bendheim on Q1 2021 Results - Earnings Call Transcript
seekingalpha.com - November 7 at 12:43 AM
Phibro: Fiscal 1Q Earnings SnapshotPhibro: Fiscal 1Q Earnings Snapshot
chron.com - November 5 at 8:22 AM
Phibro Animal Health Corp (A) hosts conference call for investorsPhibro Animal Health Corp (A) hosts conference call for investors
markets.businessinsider.com - November 4 at 7:17 PM
How Is Phibro Animal Healths (NASDAQ:PAHC) CEO Paid Relative To Peers?How Is Phibro Animal Health's (NASDAQ:PAHC) CEO Paid Relative To Peers?
uk.news.yahoo.com - October 2 at 1:49 PM
Phibro Animal Health Corporation to Host Webcast and Conference Call on September 2020 Quarterly Financial ResultsPhibro Animal Health Corporation to Host Webcast and Conference Call on September 2020 Quarterly Financial Results
benzinga.com - October 1 at 6:49 PM
DateCompanyBrokerageAction
1/2/2020Aclaris TherapeuticsSVB LeerinkReiterated Rating
10/11/2019Aclaris TherapeuticsWilliam BlairReiterated Rating
9/6/2019Aclaris TherapeuticsJMP SecuritiesDowngrade
8/9/2019Aclaris TherapeuticsCantor FitzgeraldReiterated Rating
1/29/2021Lexicon PharmaceuticalsWedbushDowngrade
1/29/2021Lexicon PharmaceuticalsJPMorgan Chase & Co.Upgrade
1/15/2021Lexicon PharmaceuticalsG.ResearchDowngrade
1/15/2021Lexicon PharmaceuticalsCitigroupBoost Price Target
1/15/2021Lexicon PharmaceuticalsGabelliDowngrade
1/14/2021Lexicon PharmaceuticalsSmith Barney CitigroupBoost Price Target
12/8/2020Lexicon PharmaceuticalsCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellUpgrade
4/27/2020Lexicon PharmaceuticalsNeedham & Company LLCReiterated Rating
2/18/2021Syndax PharmaceuticalsB. RileyInitiated Coverage
12/7/2020Syndax PharmaceuticalsMorgan StanleyBoost Price Target
12/7/2020Syndax PharmaceuticalsBTIG ResearchBoost Price Target
12/7/2020Syndax PharmaceuticalsBarclaysBoost Price Target
12/2/2020Syndax PharmaceuticalsStifel NicolausInitiated Coverage
5/25/2020Syndax PharmaceuticalsNomuraReiterated Rating
5/22/2020Syndax PharmaceuticalsHC WainwrightDowngrade
4/28/2020Syndax PharmaceuticalsRobert W. BairdBoost Price Target
3/26/2020Syndax PharmaceuticalsNomura SecuritiesReiterated Rating
3/15/2021Five Prime TherapeuticsGuggenheimReiterated Rating
3/10/2021Five Prime TherapeuticsJefferies Financial GroupReiterated Rating
3/4/2021Five Prime TherapeuticsRoth CapitalDowngrade
3/4/2021Five Prime TherapeuticsWells Fargo & CompanyDowngrade
8/12/2020Five Prime TherapeuticsCowenReiterated Rating
5/8/2020Phibro Animal HealthCredit Suisse GroupLower Price Target
8/29/2019Phibro Animal HealthBank of AmericaLower Price Target
(Data available from 4/12/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.